Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for HLBBF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
March 31, 2026 23.60%
December 31, 2025 -0.46%
September 30, 2025 17.76%
June 30, 2025 16.28%
March 31, 2025 17.76%
December 31, 2024 10.63%
September 30, 2024 13.56%
June 30, 2024 14.05%
March 31, 2024 18.99%
December 31, 2023 2.69%
September 30, 2023 13.65%
June 30, 2023 12.15%
March 31, 2023 17.45%
December 31, 2022 6.65%
September 30, 2022 14.58%
June 30, 2022 11.28%
March 31, 2022 9.42%
December 31, 2021 -0.05%
September 30, 2021 8.00%
June 30, 2021 9.55%
March 31, 2021 14.53%
December 31, 2020 12.94%
September 30, 2020 9.25%
June 30, 2020 11.97%
March 31, 2020 2.02%
Date Value
December 31, 2019 3.19%
September 30, 2019 18.16%
June 30, 2019 18.56%
March 31, 2019 21.21%
December 31, 2018 15.59%
September 30, 2018 22.77%
June 30, 2018 21.24%
March 31, 2018 26.15%
December 31, 2017 12.59%
September 30, 2017 20.15%
June 30, 2017 14.20%
March 31, 2017 13.94%
December 31, 2016 11.36%
September 30, 2016 8.11%
June 30, 2016 6.18%
March 31, 2016 4.93%
December 31, 2015 -12.06%
September 30, 2015 -34.31%
June 30, 2015 -107.6%
March 31, 2015 -2.27%
December 31, 2014 -19.49%
September 30, 2014 0.16%
June 30, 2014 4.18%
March 31, 2014 9.23%
December 31, 2013 0.64%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Novo Nordisk A/S 50.15%
ALK-Abello A/S 24.68%
AstraZeneca PLC 20.15%
ANI Pharmaceuticals, Inc. 11.55%
Corcept Therapeutics, Inc. -18.92%